Clonal hematopoiesis of indeterminate potential (CHIP) is a known risk factor for coronary artery disease, though its precise role in disease progression continues to emerge. This study leverages ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel ...

Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...

Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.

How they’re doing it: The new company, called Preventive, is being formed to research so-called “heritable genome editing,” ...

A lthough still in its early days, CRISPR has already been called the most powerful scientific tool of the century. Using ...

Quantabio has launched the sparQ™ Lysis Kit, designed to isolate high-quality, double-stranded genomic DNA from dried blood spot (DBS) samples.

Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

Professor David Williams, a New Zealander working on gene therapy at UCLA, has warned that the Bill is “unfair to farmers” and based on false assumptions about precision and safety. He points to ...